Announcements

HBSN(IF: 7.293) Call for paper: combination therapy for HCC or Biliary tract cancer

Published: 2021-09-07

Call for Original/Review/Meta Articles

New combination therapies, for instance using TKI+ICI for the advanced stage /unresectable HCC and Biliary tract cancers are increasingly interesting in the field recently. Many different combinations including TKI, ICI, radiotherapy, TACE, abolitions, HAIC, SIRT, as well as chemotherapy have brought significant benefits for those cancer patients, and hope for the longer survival. Yet more evidences need to be accumulated.

Here, HBSN journal (IF: 7.293) is calling for high-quality original articles of clinical research, especially RCT research or comprehensive review/Meta analysis on the topics of combination therapies for advanced/unresectable HCC or Biliary tract cancer. After submitted, these articles will be first reviewed by Editor-in-Chief or Vice Editor-in-Chief, and the process will go more effectively.

Submission:

Yilei Mao
Editor-in-Chief
Hepatobiliary Surgery & Nutrition (HBSN)